306-NSD2 targeting reverses plasticity in prostate cancer
The paper details research into the molecular mechanisms driving resistance to androgen receptor (AR) pathway inhibitors, such as enzalutamide, in advanced Castration-Resistant Prostate Cancer (CRPC). The study specifically addresses the lineage plasticity through which tumors can transdifferentiate into the highly resistant neuroendocrine subtype (CRPC-NE). Investigators identified that the epigenetic regulator NSD2 is significantly upregulated in CRPC-NE, correlating with poor patient survival and driving this shift by increasing H3K36me2 histone marks. Using mouse and human organoid…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.